OSCR Q2 Deep Dive: Individual Market Growth and AI Investments Shape Outlook

Health insurance company Oscar Health (NYSE:OSCR) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 70.4% year on year to $4.88 billion. Its non-GAAP profit of $1.10 per share was significantly above analysts’ consensus estimates.

Is now the time to buy OSCR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Oscar Health’s second quarter saw results well above Wall Street’s expectations, yet the market response was notably negative. Management credited disciplined pricing, technology-driven cost efficiencies, and strong execution in the individual health insurance market for driving year-over-year revenue and margin improvement. CEO Mark Bertolini highlighted that “disciplined pricing, differentiated consumer products and a scalable technology platform” fueled growth, with membership up 46% and administrative cost ratios reaching historic lows. The company cited favorable medical utilization and risk adjustment dynamics as further contributors to the positive results.

Looking forward, Oscar Health’s updated outlook is built on continued technology integration, especially AI-powered cost controls and operational efficiency. Management emphasized that expansion in the gig and part-time worker market, ongoing adoption of products like ICHRAx, and further AI deployment will remain central to its growth strategy. Bertolini noted, “As that market evolves, we see it as a huge opportunity for ICHRA in expanding the total TAM of the marketplace.” However, management acknowledged cautiousness regarding the impact of CMS eligibility reviews on membership churn and the need to closely monitor utilization trends in the coming quarters.

Key Insights from Management’s Remarks

Oscar Health’s management attributed the quarter’s performance to robust membership growth, cost discipline, and AI-driven efficiency, while emphasizing ongoing market and regulatory dynamics.

• Membership and product growth: Management pointed to above-market open enrollment and strong retention as key drivers, with 2.96 million members and growing traction in new segments like small business ICHRA (Individual Coverage Health Reimbursement Arrangements), targeting gig and part-time workers.
• AI and technology utilization: Oscar’s proprietary Oswell Agent uses member data to guide care decisions and has begun piloting radiology navigation, saving members on average $75 per appointment. About 1 in 4 members choose Oswell’s recommended site of care. AI-powered claims processing achieved 98.7% first pass accuracy, and most claims are processed within 48 hours.
• Expense management: The SG&A expense ratio reached a record low due to technology-driven efficiencies and fixed cost leverage. Management stated these improvements allow the company to scale with minimal incremental headcount, bolstering operating margins.
• Favorable risk adjustment and morbidity trends: Early 2026 market data from CMS and Wakely indicated morbidity and risk adjustment outcomes were better than priced assumptions, contributing to margin expansion. However, management exercised caution given only four months of claims data.
• Regulatory and market environment: Management discussed the effects of CMS program integrity efforts, expecting further membership churn in the back half of the year. They see continued opportunity for market share gains as the individual market stabilizes and expands, especially through new products and partnerships like ICHRAx.

Drivers of Future Performance

Oscar Health’s guidance is shaped by further technology adoption, evolving regulatory impacts, and shifts in market composition.

• AI-driven operational efficiency: Management expects increased AI integration to further reduce SG&A costs and improve medical cost management, aiming for enhanced operating leverage as membership grows without proportional headcount increases.
• Membership dynamics and CMS policies: Anticipated membership churn in the second half, driven by CMS program integrity reviews, is a headwind. Management expects churn rates to approach twice the typical 1%-2% monthly average, but views this as a timing shift rather than a structural decline.
• Expansion in new market segments: The company is investing in ICHRA and new employer platforms to target small business and gig economy participants. Management sees this as a significant long-term growth driver, given the growing trend away from traditional employer insurance and the scalability of Oscar’s technology platform.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely watch (1) the impact of CMS eligibility reviews on churn and membership stability, (2) the scaling of AI-powered tools for claims and care navigation, and (3) the adoption and profitability of the ICHRAx platform targeting small businesses and gig workers. Execution on product innovation and operational efficiency will also be key for sustained margin improvement.

Oscar Health currently trades at $26.52, down from $30.50 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.